Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 28, 2007

Molecular Partners Inks DRP Technology Agreement with Roche

  • Molecular Partners signed a collaboration agreement with Roche covering the DRP technology for a variety of undisclosed applications. Under this agreement, Molecular Partners will select DARPins to a variety of different targets, which will be provided by Roche. Roche will carry out further analyses and development. The targets and further financial terms of the agreement were not disclosed.

    DARPins constitute a novel class of binding proteins based on Molecular Partners’ designed repeat protein (DRP) technology. Due to their small size and outstanding affinity, selectivity, and stability profiles, as well as their favorable production properties in bacteria, DARPins are one of the most promising non-antibody scaffolds for in vitro and in vivo applications, according to the company.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »